Kugura bihamye kubakiriya CAS 782487-28-9 Rosiptor Ubwiza Bwiza Igiciro Cyiza Igurisha Igicuruzwa Umutekano wohereza ibicuruzwa Byera cyane 99% -copy

Ibicuruzwa byumwimerere bya semaglutide byakozwe na Novo Nordisk kandi byerekanwa kubantu bakuze barwaye diyabete yo mu bwoko bwa 2. Izina ryubucuruzi bwibicuruzwa byatewe inshinge ni Ozempic®, ishobora gukoreshwa rimwe mu cyumweru. Yemejwe ku isoko n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) ku ya 5 Ukuboza 2017, n’ikigo cy’ubuvuzi cy’Uburayi (EMA) ku ya 8 Gashyantare 2018. Byemejwe ko byamamaza n’ikigo cy’Ubuyapani gishinzwe imiti n’ibikoresho by’ubuvuzi ( PMDA) ku ya 23 Werurwe 2018. Izina ryibicuruzwa bya chimique byibicuruzwa byo mu kanwa, Rybelsus®, byemejwe na FDA ku ya 20 Nzeri 2019, EMA y’Uburayi muri Werurwe 2020, n’Ubuyapani PMDA muri Kamena 2020. Niwo muti wa mbere ku isi GLP- 1. Semaglutide (0.5 mg cyangwa inshinge 1 mg) irashobora gukoreshwa mu kuvura diyabete yo mu bwoko bwa 2 ku bantu bakuru. Uyu muti ni glucagon imeze nka peptide (GLP-1) reseptor agonist, itera ururenda rwa insuline kandi igabanya ururenda rwa glucagon. Igice cya kabiri cyubuzima bwo guhuza alubumu yamaraso nicyumweru 1, bityo rero igomba gutangwa rimwe mucyumweru ikaramu yuzuye. Ifasha indyo na siporo kunoza isukari mu maraso ku bantu bakuru barwaye diyabete yo mu bwoko bwa 2.